Abiopharma

dividend

Management and officers – staffing as of 27.3.26

The company’s liability position as of 31.12.25, by maturity dates

Periodic and annual report for 2025

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Groupe Colabor Inc. fait le point sur son processus de vente et de sollicitation d’investissements

Colabor Group Inc. Provides Update on Its SISP

dividend

The company’s liability balance as of 31.12.25, by maturity dates

Periodic and annual report for 2025